Stock listing
TWSE:1789 ScinoPharm Taiwan, Ltd. (神隆) 股價
Follow ScinoPharm Taiwan, Ltd. into a list and get an email when it puts out news.
Share price · TWSE:1789
$16.85 TWD -1.90 (-10.1%)
Close on Nov 20, 2026
- Day range
- $16.85 – $18.00 TWDNov 20, 2026
- Volume
- 1.35M sharesNov 20, 2026
- Market cap
- $13.32B TWDAt the close on Nov 20, 2026 · price × 790.7M shares outstanding
- 52-week range
- $16.70 – $29.10 TWDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $10.69M TWDMedian day 422,591 shares · 1 day with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · TWSE:1789 · TWD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $16.85 | -1.90 | -10.1% | $18.00 | $18.00 | $16.85 | 1,353,825 | |
| $18.75 | -0.40 | -2.1% | $19.35 | $19.35 | $18.65 | 570,608 | |
| $19.15 | -0.50 | -2.5% | $19.60 | $19.80 | $19.00 | 552,207 | |
| $19.65 | -0.05 | -0.3% | $19.80 | $20.35 | $19.55 | 834,424 | |
| $19.70 | +0.05 | +0.3% | $19.65 | $20.05 | $19.50 | 568,286 | |
| $19.65 | -0.35 | -1.8% | $20.05 | $20.05 | $19.55 | 754,788 | |
| $20.00 | -0.25 | -1.2% | $20.20 | $20.20 | $19.75 | 719,843 | |
| $20.25 | -0.60 | -2.9% | $20.40 | $20.70 | $19.85 | 1,180,519 | |
| $20.85 | +0.70 | +3.5% | $19.85 | $21.05 | $19.80 | 1,587,052 | |
| $20.15 | +0.70 | +3.6% | $18.50 | $20.40 | $18.35 | 1,582,181 | |
| $19.45 | -0.45 | -2.3% | $19.90 | $20.10 | $19.45 | 622,433 | |
| $19.90 | +0.10 | +0.5% | $19.80 | $20.15 | $19.40 | 627,527 | |
| $19.80 | -0.50 | -2.5% | $20.30 | $20.35 | $19.65 | 809,041 | |
| $20.30 | +0.30 | +1.5% | $20.10 | $20.30 | $19.95 | 722,046 | |
| $20.00 | +0.10 | +0.5% | $19.95 | $20.00 | $19.65 | 525,008 | |
| $19.90 | -0.10 | -0.5% | $20.00 | $20.25 | $19.90 | 595,795 | |
| $20.00 | +0.25 | +1.3% | $19.90 | $20.00 | $19.70 | 764,609 | |
| $19.75 | +0.30 | +1.5% | $19.60 | $19.80 | $19.50 | 718,648 | |
| $19.45 | 0.00 | 0.0% | $19.45 | $19.45 | $19.45 | 0 | |
| $19.45 | -0.15 | -0.8% | $19.65 | $19.70 | $19.40 | 353,027 | |
| $19.60 | +0.40 | +2.1% | $19.35 | $19.70 | $19.35 | 305,614 | |
| $19.20 | -0.10 | -0.5% | $19.00 | $19.55 | $19.00 | 378,943 | |
| $19.30 | -0.40 | -2.0% | $19.80 | $19.80 | $19.30 | 368,381 | |
| $19.70 | -0.10 | -0.5% | $20.00 | $20.20 | $19.70 | 699,966 | |
| $19.80 | -0.05 | -0.3% | $19.80 | $20.40 | $19.60 | 962,100 | |
| $19.85 | +0.45 | +2.3% | $19.40 | $19.85 | $19.35 | 425,181 | |
| $19.40 | -0.20 | -1.0% | $19.35 | $19.60 | $19.15 | 420,000 | |
| $19.60 | +0.50 | +2.6% | $19.20 | $19.95 | $19.20 | 814,040 | |
| $19.10 | +0.15 | +0.8% | $18.95 | $19.40 | $18.90 | 441,001 | |
| $18.95 | +0.30 | +1.6% | $18.65 | $19.00 | $18.65 | 325,837 | |
| $18.65 | +0.15 | +0.8% | $18.65 | $18.80 | $18.55 | 229,986 | |
| $18.50 | -0.10 | -0.5% | $18.80 | $18.80 | $18.50 | 344,085 | |
| $18.60 | -0.20 | -1.1% | $18.80 | $18.80 | $18.45 | 413,412 | |
| $18.80 | -0.15 | -0.8% | $18.80 | $18.95 | $18.70 | 276,036 | |
| $18.95 | +0.40 | +2.2% | $18.70 | $19.10 | $18.65 | 341,400 | |
| $18.55 | -0.05 | -0.3% | $18.50 | $18.90 | $18.50 | 177,044 | |
| $18.60 | -0.30 | -1.6% | $18.90 | $18.90 | $18.55 | 293,070 | |
| $18.90 | +0.05 | +0.3% | $19.00 | $19.10 | $18.90 | 182,073 | |
| $18.85 | -0.30 | -1.6% | $19.15 | $19.15 | $18.85 | 312,304 | |
| $19.15 | +0.15 | +0.8% | $19.00 | $19.30 | $18.85 | 361,117 | |
| $19.00 | -0.60 | -3.1% | $19.40 | $19.40 | $18.80 | 1,035,060 | |
| $19.60 | +1.45 | +8.0% | $18.20 | $19.85 | $18.20 | 1,627,240 | |
| $18.15 | +0.05 | +0.3% | $18.15 | $18.25 | $18.10 | 274,000 | |
| $18.10 | +0.10 | +0.6% | $18.05 | $18.10 | $17.90 | 312,040 | |
| $18.00 | -0.30 | -1.6% | $18.15 | $18.15 | $18.00 | 522,488 | |
| $18.30 | -0.30 | -1.6% | $18.50 | $18.50 | $18.15 | 841,216 | |
| $18.60 | -0.55 | -2.9% | $18.95 | $19.00 | $18.55 | 808,209 | |
| $19.15 | 0.00 | 0.0% | $19.05 | $19.30 | $19.00 | 257,050 | |
| $19.15 | -0.25 | -1.3% | $19.30 | $19.50 | $19.15 | 315,010 | |
| $19.40 | +0.30 | +1.6% | $19.40 | $19.65 | $19.10 | 550,593 | |
| $19.10 | +0.20 | +1.1% | $19.00 | $19.15 | $18.90 | 345,537 | |
| $18.90 | -0.10 | -0.5% | $18.95 | $19.20 | $18.90 | 414,200 | |
| $19.00 | 0.00 | 0.0% | $19.00 | $19.10 | $18.80 | 399,625 | |
| $19.00 | 0.00 | 0.0% | $19.00 | $19.30 | $18.95 | 363,340 | |
| $19.00 | -0.10 | -0.5% | $18.95 | $19.35 | $18.90 | 315,869 | |
| $19.10 | +0.05 | +0.3% | $19.05 | $19.20 | $19.05 | 155,504 | |
| $19.05 | 0.00 | 0.0% | $18.95 | $19.20 | $18.95 | 183,054 | |
| $19.05 | +0.10 | +0.5% | $18.95 | $19.10 | $18.90 | 274,105 | |
| $18.95 | -0.25 | -1.3% | $19.10 | $19.10 | $18.95 | 234,140 | |
| $19.20 | -0.25 | -1.3% | $19.45 | $19.45 | $19.05 | 222,776 | |
| $19.45 | 0.00 | 0.0% | $19.45 | $19.55 | $19.15 | 560,290 | |
| $19.45 | +0.50 | +2.6% | $18.95 | $19.50 | $18.95 | 699,244 |
Splits
4 splits since 2012 · TWSE:1789 · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 26-for-25 | Split | |
| 26-for-25 | Split | |
| 26-for-25 | Split | |
| 103-for-100 | Split |
- Ticker
- TWSE:1789
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- TWSE
- Currency
- TWD
What changed lately
Latest news release · Jan 5, 2026
ScinoPharm Secures U.S. FDA Approval for Glatiramer Acetate Injection for the Treatment of Multiple Sclerosis
Latest news
ScinoPharm Secures U.S. FDA Approval for Glatiramer Acetate Injection for the Treatment of Multiple Sclerosis
Jan 5, 2026
Closed $17.10 (-0.3%) on Jan 5, 2026
ScinoPharm Taiwan, Ltd. on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 1 in the last 12 months · 5 in all · newest Jan 5, 2026 · oldest 2014
- Decks
- 45 decks · latest Aug 2, 2018
Valuation
P/E 797× against a median of 27.3×: the highest of 8 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $10.70B TWD
- P/E
- 797×
- EV/sales
- 3.5×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 1.3×
- Gross margin
- 27.5%
- Operating margin
- −3.7%
- Net margin
- 0.5%
- Debt to equity
- 0.1×
- Beta
- No index for this market yet
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| ScinoPharm Taiwan, Ltd. · TWSE:1789 | US$404.3M | US$324.6M | 797× | 3.5× | n/a | 1.3× | 0.5% | 0.1× | n/a |
| Zhejiang Chengyi Pharmaceutical Co. Ltd. Class A · SSE:603811 | US$425.5M | US$398.4M | 15.0× | 3.2× | n/a | 1.9× | 22.8% | 0.0× | n/a |
| Harbin Medisan Pharmaceutical Co., Ltd. Class A · SZSE:002900 | US$412.2M | US$376.5M | n/a | 3.0× | n/a | 1.6× | −27.1% | 0.1× | n/a |
| PKU Healthcare Corp. Ltd. Class A · SZSE:000788 | US$411.5M | US$243.4M | 133× | 1.8× | n/a | 1.8× | 2.3% | 0.0× | n/a |
| CorMedix Inc. · NASDAQ:CRMD | US$410.8M | US$201.0M | 6.4× | 0.5× | 1.0× | 0.9× | 15.5% | 0.3× | 0.71 |
| Huaren Pharmaceutical Co., Ltd. Class A · SZSE:300110 | US$409.0M | US$444.4M | n/a | 2.4× | n/a | 3.2× | −40.2% | 0.5× | n/a |
| Handa Pharmaceuticals Inc · TPEX:6620 | US$405.9M | US$292.7M | 27.3× | 8.0× | 15.6× | 2.7× | 40.5% | 0.0× | n/a |
| Zhuhai Rundu Pharmaceutical Co. Ltd. Class A · SZSE:002923 | US$400.7M | US$380.9M | 47.1× | 1.9× | n/a | 2.4× | 4.2% | 0.2× | n/a |
| Cheng Du Sheng Nuo Biotec Co., Ltd. Class A · SSE:688117 | US$397.6M | US$405.9M | 12.7× | 2.8× | n/a | 2.3× | 21.8% | 0.3× | n/a |
| Kexing Biopharm Co., Ltd. Class A · SSE:688136 | US$397.2M | US$409.6M | 35.7× | 2.1× | n/a | 1.5× | 5.7% | 0.4× | n/a |
| Shaanxi Kanghui Pharmaceutical Co. , Ltd. Class A · SSE:603139 | US$392.2M | US$396.0M | n/a | 5.1× | n/a | 3.9× | −38.4% | 0.2× | n/a |
| Median of the others | US$407.4M | US$388.4M | 27.3× | 2.6× | 8.3× | 2.1× | 4.9% | 0.2× | 0.71 |
Forecasts
Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.
- Price target
- 18.00 TWD · Analysts' mean
- EPS, year to Dec 2026
- 0.40 · 1 analyst
Events
| Quarter | Results | Share move |
|---|---|---|
| Q4 2025 | Mar 5, 2026 · After close | +6.7% |
| Q3 2025 | Nov 3, 2025 · Before open | −0.8% |
| Q2 2025 | Aug 5, 2025 · After close | −0.8% |
| Q1 2025 | May 6, 2025 · After close | −0.3% |
| Q4 2024 | Feb 25, 2025 · After close | −0.7% |
| Q4 2023 | Feb 26, 2024 · After close | −0.8% |
| Q3 2023 | Nov 7, 2023 · After close | −5.1% |
| Q2 2023 | Aug 7, 2023 · Before open | +1.1% |
| Q1 2023 | May 10, 2023 · After close | −4.5% |
| Q4 2022 | Feb 28, 2023 · After close | +0.6% |
All 18 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q3 2022 | Nov 8, 2022 · After close | +0.6% |
| Q2 2022 | Aug 5, 2022 · After close | +1.6% |
| Q1 2022 | May 6, 2022 · After close | −2.5% |
| Q4 2021 | Feb 25, 2022 · Before open | +1.3% |
| Quarter to Sep 30, 2021 | Nov 9, 2021 · After close | −0.8% |
| Quarter to Jun 30, 2021 | Aug 10, 2021 · After close | −0.8% |
| Quarter to Mar 31, 2021 | May 10, 2021 · After close | −3.0% |
| Quarter to Dec 31, 2020 | Mar 18, 2021 · After close | −1.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| H1 2018 Earnings Presentation | Earnings | 23 slides | Aug 2, 2018 |
| H1 2018 Earnings Presentation | Earnings | 23 slides | Aug 2, 2018 |
| Q4 2017 Earnings Presentation | Earnings | 36 slides | Feb 23, 2018 |
| Q4 2017 Earnings Presentation | Earnings | 36 slides | Feb 23, 2018 |
| JPMorgan Healthcare Conference 2018 | Conference | 38 slides | Jan 8, 2018 |
| JPM Healthcare Conference 2018 | Conference | 38 slides | Jan 8, 2018 |
| Investor Presentation (November 2017) | Investor deck | 38 slides | Nov 29, 2017 |
| Investor Presentation (November 2017) | Investor deck | 38 slides | Nov 29, 2017 |
| 2016 JP Morgan Healthcare Conference | Conference | 25 slides | Jan 14, 2016 |
| Investor Presentation (October 2015) | Investor deck | 27 slides | Oct 8, 2015 |
All 45 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Fact Sheet (2014) | Fact sheet | 3 slides | Sep 15, 2014 |
| Q1 2014 Earnings Presentation | Earnings | 32 slides | May 9, 2014 |
| Q1 2014 Earnings Presentation | Earnings | 32 slides | May 9, 2014 |
| Investor Presentation (April 2014) | Investor deck | 23 slides | Apr 9, 2014 |
| FY2013 Earnings Presentation | Earnings | 23 slides | Apr 9, 2014 |
| Investor Presentation (March 2014) | Investor deck | 33 slides | Mar 24, 2014 |
| Investor Presentation (March 2014) | Investor deck | 30 slides | Mar 24, 2014 |
| Investor Presentation (February 2014) | Investor deck | 23 slides | Feb 14, 2014 |
| Investor Presentation (November 2013) | Investor deck | 26 slides | Nov 12, 2013 |
| Q3 2013 Earnings Presentation | Earnings | 26 slides | Nov 12, 2013 |
| Q2 2013 Earnings Presentation | Earnings | 32 slides | September 2013 |
| Q2 2013 Earnings Presentation | Earnings | 31 slides | Aug 7, 2013 |
| Q2 2013 Earnings Presentation | Earnings | 31 slides | Aug 7, 2013 |
| Q1 2013 Earnings Presentation | Earnings | 24 slides | May 10, 2013 |
| Q1 2013 Earnings Presentation | Earnings | 33 slides | May 2013 |
| FY2012 Earnings Presentation | Earnings | 35 slides | Mar 27, 2013 |
| FY2012 Earnings Presentation | Earnings | 35 slides | Jan 30, 2013 |
| Investor Presentation (January 2013) | Investor deck | 37 slides | Jan 9, 2013 |
| Investor Presentation (January 2013) | Investor deck | 38 slides | January 2013 |
| Investor Presentation (January 2013) | Investor deck | 35 slides | January 2013 |
| Investor Presentation (October 2012) | Investor deck | 37 slides | Oct 29, 2012 |
| DB Conference 2012 | Conference | 26 slides | Aug 31, 2012 |
| 1H 2012 Earnings Presentation | Earnings | 36 slides | Aug 23, 2012 |
| Investor Presentation (August 2012) | Investor deck | 35 slides | Aug 23, 2012 |
| Q1 2012 Earnings Presentation | Earnings | 28 slides | Jul 10, 2012 |
| Q1 2012 Earnings Presentation | Earnings | 26 slides | July 2012 |
| Citi Conference 2012 | Conference | 26 slides | May 8, 2012 |
| Investor Presentation (April 2012) | Investor deck | 36 slides | Apr 18, 2012 |
| Investor Presentation (April 2012) | Investor deck | 37 slides | Apr 18, 2012 |
| Investor Presentation (March 2012) | Investor deck | 31 slides | Mar 14, 2012 |
| Investor Presentation (March 2012) | Investor deck | 27 slides | Mar 14, 2012 |
| J.P. Morgan Healthcare Conference 2012 | Conference | 25 slides | Jan 12, 2012 |
| J.P. Morgan Healthcare Conference 2012 | Conference | 28 slides | Jan 9, 2012 |
| Q3 2011 Earnings Presentation | Earnings | 31 slides | November 2011 |
| IPO Roadshow (September 2011) | IPO roadshow | 41 slides | September 2011 |
Financials
Annual, in TWD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.16B | 3.41B | 3.19B | 3.26B | 2.76B | 3.08B | 2.89B | 3.52B | 3.52B | 4.03B |
| Cost of revenue | 2.07B | 2.11B | 1.97B | 2.01B | 1.48B | 1.77B | 1.72B | 1.98B | 1.97B | 2.22B |
| Gross profit | 1.10B | 1.30B | 1.22B | 1.25B | 1.28B | 1.32B | 1.18B | 1.54B | 1.55B | 1.81B |
| Research and development | 497.3M | 459.4M | 357.7M | 271.3M | 306.0M | 245.6M | 238.4M | 313.2M | 314.3M | 279.6M |
| Selling, general and administrative | 363.2M | 376.4M | 364.2M | 406.5M | 532.2M | 525.4M | 513.8M | 524.0M | 531.2M | 488.1M |
| Operating income | 108.9M | 322.7M | 314.5M | 405.6M | 288.7M | 375.5M | 267.1M | 558.3M | 559.0M | 868.3M |
| Depreciation and amortization | 516.7M | 488.3M | 461.2M | 439.5M | 381.5M | 393.2M | 408.7M | 405.8M | 432.5M | 444.8M |
| EBITDA | 625.6M | 811.0M | 775.7M | 845.1M | 670.3M | 768.7M | 675.8M | 964.1M | 991.5M | 1.31B |
| Interest expense | 9.87M | 8.08M | 9.15M | 7.91M | 6.55M | 15.2M | 55.7M | 80.2M | 76.6M | 36.1M |
| Income before tax | 147.4M | 413.0M | 348.8M | 438.0M | 302.3M | 358.5M | 265.1M | 490.5M | 475.3M | 810.6M |
| Income tax | 10.4M | 73.7M | 61.8M | 84.7M | 58.8M | 76.4M | 48.4M | 47.6M | 52.9M | 151.9M |
| Net income | 137.0M | 339.4M | 287.1M | 353.2M | 243.5M | 282.1M | 216.7M | 443.0M | 422.4M | 658.7M |
| Earnings per share, basic | 0.17 | 0.43 | 0.36 | 0.45 | 0.31 | 0.36 | 0.27 | 0.56 | 0.53 | 0.83 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 3.11B | 4.17B | 3.94B | 4.29B | 4.08B | 4.05B | 3.30B | 4.20B | 3.91B | 3.71B |
| Short-term investments | 90.0K | 8.30M | 51.1M | 50.7M | 34.3M | 175.1M | 179.0M | 443.3M | 417.0M | |
| Receivables | 624.0M | 654.2M | 779.9M | 653.5M | 393.0M | 472.9M | 670.5M | 663.0M | 764.9M | 836.3M |
| Inventory | 1.64B | 1.67B | 1.51B | 1.19B | 1.35B | 1.25B | 1.12B | 1.36B | 1.68B | 1.83B |
| Current assets | 5.49B | 6.61B | 6.38B | 6.32B | 5.97B | 5.92B | 5.41B | 6.51B | 6.47B | 6.59B |
| Property, plant and equipment | 4.50B | 4.65B | 4.84B | 5.11B | 4.76B | 5.09B | 5.21B | |||
| Total assets | 11.9B | 11.9B | 11.7B | 11.9B | 11.7B | 11.8B | 11.7B | 12.6B | 12.7B | 12.8B |
| Accounts payable | 62.5M | 81.0M | 101.3M | 125.3M | 69.7M | 159.7M | 101.0M | 89.4M | 90.8M | 69.7M |
| Current liabilities | 709.8M | 767.7M | 729.5M | 803.1M | 556.3M | 686.6M | 741.7M | 1.95B | 1.12B | 1.69B |
| Long-term debt | 0 | 1.10B | 770.9M | |||||||
| Total debt | 762.7M | 676.8M | 621.1M | 677.9M | 557.6M | 577.3M | 697.2M | 1.41B | 1.69B | 1.79B |
| Total liabilities | 1.33B | 1.42B | 1.36B | 1.46B | 1.18B | 1.32B | 1.41B | 2.02B | 2.28B | 2.56B |
| Shareholders' equity | 10.5B | 10.5B | 10.4B | 10.5B | 10.5B | 10.5B | 10.3B | 10.5B | 10.4B | 10.2B |
| Shares outstanding | 805.6M | 792.9M | 792.3M | 792.7M | 792.3M | 792.2M | 792.1M | 793.1M | 792.6M | 793.7M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 597.1M | 750.9M | 231.1M | 773.8M | 509.8M | 946.3M | 788.9M | 1.23B | 971.7M | 1.67B |
| Capital spending | -291.3M | -288.7M | -284.7M | -250.0M | -321.3M | -183.1M | -105.7M | -127.0M | -410.9M | -458.5M |
| Free cash flow | 305.8M | 462.2M | -53.6M | 523.7M | 188.5M | 763.2M | 683.2M | 1.10B | 560.8M | 1.21B |
| Cash from investing | -1.45B | -293.4M | -233.3M | -253.6M | -70.0M | 241.7M | -98.4M | -300.0M | -437.3M | -202.3M |
| Cash from financing | -203.5M | -244.9M | -341.0M | -314.8M | -412.8M | -444.9M | -1.57B | -627.0M | -313.9M | -137.6M |
| Dividends paid | -276.8M | -237.2M | -284.7M | -379.6M | -395.4M | -213.5M | -387.5M | -379.6M | -228.1M | -219.3M |
| Change in cash | -1.06B | 224.5M | -353.2M | 213.8M | 26.0M | 750.0M | -898.4M | 292.5M | 203.6M | 1.37B |
Cap table
Built by 6ix from ScinoPharm Taiwan, Ltd.’s releases
- Common shares
- 790,739,000
- Fully diluted
- 790,739,000
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 790,739,000 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 790,739,000 |
Log in to ask 6ix AI your own questions about ScinoPharm Taiwan, Ltd.